Climb Bio reports Q3 2026 results, dosing underway in IgAN Phase 2 trialNov 5Quarterly updatebudoprutugClimb Bio, Inc.
Climb Bio reports early PrisMN Phase 2 data for budoprutug in kidney diseaseOct 26Clinical readoutbudoprutugClimb Bio, Inc.
Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 startAug 6Quarterly updateClimb Bio, Inc.